Microbiota transplantation: concept, methodology and strategy for its modernization
Open accessThe DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Fecal microbiota transplantation (FMT) has become a research focus of biomedicine and clinical medicine in recent years. The clinical response from FMT for different diseases provided evidence for microbiota-host interactions associated with various disorders, including Clostridium difficile infection, inflammatory bowel disease, diabetes mellitus, cancer, liver cirrhosis, gut-brain disease and others. To discuss the experiences of using microbes to treat human diseases from ancient China to current era should be important in moving standardized FMT forward and achieving a better future. Here, we review the changing concept of microbiota transplantation from FMT to selective microbiota transplantation, methodology development of FMT and step-up FMT strategy based on literature and state experts' perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 1×
“A new research found that gut microbiome improved efficacy of PD-1-based immunotherapy against epithelial tumors (Routy et al., 2018), implying that FMTcan be used to fight against cancer.”
BackgroundGibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., et al. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.75 · Cited by 5,634 · cited 1×
“A single microbe has a weak ability in the prevention and treatment of human diseases, though researches have proven its efficacy in standard animal models (Gibson et al., 2017).”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Another study (Gopalakrishnan et al., 2018) also demonstrated enhanced systemic immunity and favorable gut microbiome profile in patients showing good response to PD-1 immunotherapy, as well as in germ-free mice receiving fecal transplants from responding patients.”
BackgroundDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“In an RCT study, these two rates become 81% and 94% of resolution of CDI after the first FMT and repeat FMTs (van Nood et al., 2013).”
BackgroundThe Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637 · cited 2×
“Fecal microbiota transplantation (FMT), a concrete evidence proving the role of microbiota in many diseases, has recently become a research focus in biomedicine and clinical medicine (Khoruts and Sadowsky 2016; Lynch and Pedersen 2016; Vindigni and Surawicz 2017).”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 2×
“Infect Control Hosp Epidemiol 36:438–444 Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1×
“A significant association has been observed between commensal microbial composition and clinical response of anti-PD-L1 therapy in metastatic melanoma patients (Matson et al., 2018).”
BackgroundVrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913 · cited 1×
“…reported the method and efficacy of using frozen fecal microbiota for C. difficile infection The improved methodology for storing fecal microbiota 2012 (Vrieze et al., 2012) Vrieze et al. from the Netherland reported the FMT in metabolic syndrome The evidence to use FMT in changing insulin…”
MethodFusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198 · cited 1×
“The bioinformatic and functional studies demonstrated that Fusobacterium nucleatum enhanced the resistance of colorectal cancer to chemotherapy (Yu et al., 2017).”
BackgroundGuidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 2×
“Besides, trials have revealed its potential role in dealing with refractory ulcerative colitis (Cui et al., 2015b; Kellermayer et al., 2015; Moayyedi et al., 2015; Rossen et al., 2015), Crohn’s disease (Zhang et al., 2013; Cui et al., 2015a; Shimizu et al., 2016; Bak et al., 2017; He et al., 2017a,…”
BackgroundKang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391 · cited 2×
“, 2017), autism (Kang et al., 2017) and epilepsy (He et al.”
BackgroundParamsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276 · cited 1×
“Paramsothy et al. (2017) reported that FMT with intensive doses and multiple donors induced clinical remission and endoscopic improvement in active ulcerative colitis and this treatment was associated with distinct microbial changes.”
BackgroundGong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273 · cited 1×
“Food and Drug Administration (FDA) has approved indications of anti-PD-1 and anti-PD-L1 therapies in cancer based on some registered trials (Gong et al., 2018).”
BackgroundEuropean consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Chu, D. M., Ma, J., Prince, A. L., Antony, K. M., Seferovic, M. D., & Aagaard, K. M. (2017) · Nature Medicine · doi:10.1038/nm.4272 · Cited by 1,063 · cited 2×
“A recent study (Chu et al., 2017a, b) reported that some preparation methods can damage the content of living fecal microbes and the suitability of clinical fecal materials.”
Background(1958) · PubMed · Cited by 978
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970 · cited 1×
“Microbiota could be modified in clinical practice to improve its efficacy and reduce the toxic burden of these compounds (Alexander et al., 2017).”
BackgroundRossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 2×
“…have revealed its potential role in dealing with refractory ulcerative colitis (Cui et al., 2015b; Kellermayer et al., 2015; Moayyedi et al., 2015; Rossen et al., 2015), Crohn’s disease (Zhang et al., 2013; Cui et al., 2015a; Shimizu et al., 2016; Bak et al., 2017; He et al., 2017a, b),…”
BackgroundDaillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897 · cited 1×
“Enterococcus hirae and Barnesiella intestinihominis can strengthen Cyclophosphamide-induced therapeutic immunomodulatory effects in cancer (Daillere et al., 2016).”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 6×
“For example, the method in Hamilton’s report in 2012 could be called as FPC (Hamilton et al., 2012), and the automatic method using purification system based on GenFMTer (FMT Medical, Nanjing, China) as MPC (He et al.”
BackgroundMethodResultInfluentialPetrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731 · cited 1×
“The microbial ecosystem therapeutic (MET-1, or “RePOOPulate”) in pilot trials showed an attractive response (Petrof et al., 2013; Martz et al., 2017).”
BackgroundBrandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 2×
“The potential cardiometabolic diseases, autoimmune diseases and neurological diseases have been discussed (Brandt et al., 2012; Kelly et al. 2015).”
BackgroundKelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636 · cited 1×
“An analysis based on 80 patients demonstrates that FMT is safe in immunocompromised cases (Kelly et al., 2014).”
MethodWong, S. H., Zhao, L., Zhang, X., Nakatsu, G., Han, J., Xu, W., Xiao, X., Kwong, T. N. Y., Tsoi, H., Wu, W. K. K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.022 · Cited by 634 · cited 1×
“Wong et al. (2017) reported that the fecal microbiota from patients with colon cancer promoted tumorigenesis in germfree and carcinogenic mice.”
BackgroundBajaj, J. S., Kassam, Z., Fagan, A., Gavis, E. A., Liu, E., Cox, I. J., Kheradman, R., Heuman, D., Wang, J., Gurry, T., et al. (2017) · Hepatology · doi:10.1002/hep.29306 · Cited by 633 · cited 1×
“…2017; He et al., 2017a, b), constipation (Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al., 2018), liver disease (Kao et al., 2016; Bajaj et al., 2017; Philips et al., 2017; Ren et al., 2017), blood disease (Kakihana et al., 2016; Spindelboeck et al., 2017), autism (Kang et al.,…”
BackgroundYoungster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629 · cited 1×
“Oral intake of microbiota capsules is a mean of delivery through the upper gut (Youngster et al., 2014; Lee et al., 2016).”
BackgroundLee, C. H., Steiner, T., Petrof, E. O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J. S., Collins, S., Moayyedi, P., Crowther, M., et al. (2016) · JAMA · doi:10.1001/jama.2015.18098 · Cited by 627
Should we standardize the 1,700-year-old fecal microbiota transplantation?
Zhang, F., Luo, W., Shi, Y., Fan, Z., & Ji, G. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.251 · Cited by 619 · cited 15×
“…in the book “Zhou Hou Bei Ji Fang” The clear methods and indications supported the wide practice in the following 1,700 years in China 1590 (Li 2011; Zhang et al., 2012b) Li Shizhen, a Chinese doctor described more than 20 conditions effectively treated by fecal water or fermented fecal matter in…”
BackgroundInfluentialSelf-citationUpdate on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572 · cited 1×
“The potential cardiometabolic diseases, autoimmune diseases and neurological diseases have been discussed (Brandt et al., 2012; Kelly et al. 2015).”
BackgroundUnderstanding the mechanisms of faecal microbiota transplantation
Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 561 · cited 2×
“Fecal microbiota transplantation (FMT), a concrete evidence proving the role of microbiota in many diseases, has recently become a research focus in biomedicine and clinical medicine (Khoruts and Sadowsky 2016; Lynch and Pedersen 2016; Vindigni and Surawicz 2017).”
BackgroundJohnsen, P. H., Hilpüsch, F., Cavanagh, J. P., Leikanger, I. S., Kolstad, C., Valle, P. C., & Goll, R. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30338-2 · Cited by 437 · cited 6×
“…Cui et al., 2015a; Shimizu et al., 2016; Bak et al., 2017; He et al., 2017a, b), constipation (Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al., 2018), liver disease (Kao et al., 2016; Bajaj et al., 2017; Philips et al., 2017; Ren et al., 2017), blood disease (Kakihana et al.,…”
BackgroundInfluentialVaginal bacteria modify HIV tenofovir microbicide efficacy in African women
Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., et al. (2017) · Science · doi:10.1126/science.aai9383 · Cited by 428 · cited 2×
“The accumulating evidences have shown a potential role of microbiota in extra-intestinal sites, such as vagina (Klatt et al., 2017), sinus (Schwartz et al.”
BackgroundSystematic Review: Adverse Events of Fecal Microbiota Transplantation
Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., & Wang, B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161174 · Cited by 409
Weight Gain After Fecal Microbiota Transplantation
Alang, N., & Kelly, C. R. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv004 · Cited by 403 · cited 1×
“A woman developed new-onset obesity after receiving stool from a healthy but overweight donor (Alang and Kelly 2015).”
BackgroundKakihana, K., Fujioka, Y., Suda, W., Najima, Y., Kuwata, G., Sasajima, S., Mimura, I., Morita, H., Sugiyama, D., Nishikawa, H., et al. (2016) · Blood · doi:10.1182/blood-2016-05-717652 · Cited by 367 · cited 7×
“The important events using fecal microbiota transplantation in history History of fecal microbiota transplantation (FMT) Significance of the events The fourth century (Ge 2000; Zhang et al., 2012b) Ge Hong, a Chinese doctor described the rescue for serious food poisoning, fever, diarrhea by drinking fecal water or fer…”
BackgroundMethodInfluentialPROSPECTIVE DIAGNOSIS OF SPINA BIFIDA
Brock, D. J. H., Scrimgeour, J. B., Chard, T., Leek, A. E., Kitau, M. J., & Leighton, P. C. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91459-2 · Cited by 361
Philips, C. A., Pande, A., Shasthry, S. M., Jamwal, K. D., Khillan, V., Chandel, S. S., Kumar, G., Sharma, M. K., Maiwall, R., Jindal, A., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.029 · Cited by 349 · cited 1×
“…(Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al., 2018), liver disease (Kao et al., 2016; Bajaj et al., 2017; Philips et al., 2017; Ren et al., 2017), blood disease (Kakihana et al., 2016; Spindelboeck et al., 2017), autism (Kang et al., 2017) and epilepsy (He et al., 2017a).”
BackgroundFaecal microbiota transplantation protects against radiation‐induced toxicity
Cui, M., Xiao, H., Li, Y., Zhou, L., Zhao, S., Luo, D., Zheng, Q., Dong, J., Zhao, Y., Zhang, X., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606932 · Cited by 328 · cited 1×
“In this process, the peripheral white blood cell counts, gastrointestinal tract function and intestinal epithelial integrity were improved (Cui et al., 2017).”
BackgroundTreatment of ulcerative colitis by implantation of normal colonic flora
Bennet, J., & Brinkman, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91183-5 · Cited by 304 · cited 2×
“1989 (Bennet and Brinkman 1989; Borody et al., 1989) Bennet and Brinkman from America reported success by fecal water enema for Bennet’s ulcerative colitis; Borody et al.”
BackgroundMethodCui, B., Feng, Q., Wang, H., Wang, M., Peng, Z., Li, P., Huang, G., Liu, Z., Wu, P., Fan, Z., et al. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12727 · Cited by 298 · cited 11×
“In a recent pilot study (Cui et al., 2015a, b), 8 of 14 (57.1”
BackgroundSelf-citationFecal microbiota transplantation
Vindigni, S. M., & Surawicz, C. M. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.012 · Cited by 283
Suskind, D. L., Brittnacher, M. J., Wahbeh, G., Shaffer, M. L., Hayden, H. S., Qin, X., Singh, N., Damman, C. J., Hager, K. R., Nielson, H., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000307 · Cited by 243 · cited 2×
“reported nine cases of Crohn’s disease undergoing multiple FMTs through the nasojejunal tube (Suskind et al., 2015).”
BackgroundFecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: The first report
He, Z., Cui, B.-T., Zhang, T., Li, P., Long, C.-Y., Ji, G.-Z., & Zhang, F.-M. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3565 · Cited by 225 · cited 8×
“…(Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al., 2018), liver disease (Kao et al., 2016; Bajaj et al., 2017; Philips et al., 2017; Ren et al., 2017), blood disease (Kakihana et al., 2016; Spindelboeck et al., 2017), autism (Kang et al., 2017) and epilepsy (He et al., 2017a).”
BackgroundMethodSelf-citationBorody, T. J., George, L., Andrews, P., Brandl, S., Noonan, S., Cole, P., Hyland, L., Morgan, A., Maysey, J., & Moore‐Jones, D. (1989) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1989.tb136704.x · Cited by 221
Brodmann, T., Endo, A., Gueimonde, M., Vinderola, G., Kneifel, W., de Vos, W. M., Salminen, S., & Gómez-Gallego, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01725 · Cited by 191 · cited 1×
“The use of bacteria as probiotics has a long history (Brodmann et al., 2017).”
BackgroundJiang, Z. D., Ajami, N. J., Petrosino, J. F., Jun, G., Hanis, C. L., Shah, M., Hochman, L., Ankoma‐Sey, V., DuPont, A. W., Wong, M. C., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13969 · Cited by 182 · cited 5×
“…Cui et al., 2015a; Shimizu et al., 2016; Bak et al., 2017; He et al., 2017a, b), constipation (Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al., 2018), liver disease (Kao et al., 2016; Bajaj et al., 2017; Philips et al., 2017; Ren et al., 2017), blood disease (Kakihana et al.,…”
BackgroundInfluentialFischer, M., Kao, D., Kelly, C., Kuchipudi, A., Jafri, S.-M., Blumenkehl, M., Rex, D., Mellow, M., Kaur, N., Sokol, H., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000908 · Cited by 178 · cited 2×
“A multivariable analysis (Fischer et al., 2016a, b) demonstrates that predictors of early FMT failure include severe or severe/complicated CDI, inpatient status during FMT, and previous CDI-related hospitalization.”
BackgroundMethodRen, Y., Ye, Z., Yang, L., Jin, L., Wei, W., Deng, Y., Chen, X., Xiao, C., Yu, X., Xu, H., et al. (2017) · Hepatology · doi:10.1002/hep.29008 · Cited by 171 · cited 2×
“, 2018), liver disease (Kao et al., 2016; Bajaj et al., 2017; Philips et al., 2017; Ren et al., 2017), blood disease (Kakihana et al.”
BackgroundFischer, M., Sipe, B. W., Rogers, N. A., Cook, G. K., Robb, B. W., Vuppalanchi, R., & Rex, D. K. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13290 · Cited by 168 · cited 5×
“These reports, including Fisher’s report on severe CDI (Fischer et al., 2015), have given us a lens to see the potential of this new therapy in treating more microbiota-related diseases, especially those refractory conditions.”
BackgroundInfluentialTariq, R., Pardi, D. S., Tosh, P. K., Walker, R. C., Razonable, R. R., & Khanna, S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix618 · Cited by 165
Konijeti, G. G., Sauk, J., Shrime, M. G., Gupta, M., & Ananthakrishnan, A. N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu128 · Cited by 155 · cited 1×
“The step 2 refers to multi-FMTs and is commonly indicated to treat patients with IBD (Cui et al., 2015a, b, 2016) and partially refractory CDI (Lee et al., 2014).”
BackgroundFerreira, M. R., Muls, A., Dearnaley, D. P., & Andreyev, J. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70504-7 · Cited by 153 · cited 1×
“The effect of radiation on the gut microbiota, and the clinical implications of a modified microbial balance after radiotherapy are now beginning to emerge (Ferreira et al., 2014).”
BackgroundCui, B., Li, P., Xu, L., Zhao, Y., Wang, H., Peng, Z., Xu, H., Xiang, J., He, Z., Zhang, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0646-2 · Cited by 148
Self-citationWei, Y., Yang, J., Wang, J., Yang, Y., Huang, J., Gong, H., Cui, H., & Chen, D. (2016) · Critical Care · doi:10.1186/s13054-016-1491-2 · Cited by 147 · cited 1×
“Most commonly, step 1 involves a single FMT for treating CDI or refractory intestinal infection (Surawicz et al., 2013; Wei et al., 2016).”
BackgroundFecal microbiota transplantation in the management of hepatic encephalopathy
Kao, D., Roach, B., Park, H., Hotte, N., Madsen, K., Bain, V., & Tandon, P. (2016) · Hepatology · doi:10.1002/hep.28121 · Cited by 138 · cited 3×
“…automatic purification of microbiota from stool and the step-up FMT strategy The modernized process of FMT and improved recognition on FMT strategy 2016 (Kao et al., 2016) Kao et al. in Canada reported the FMT for hepatic encephalopathy Provides an evidence to use FMT for a liver disease 2016…”
BackgroundMethodSpindelboeck, W., Schulz, E., Uhl, B., Kashofer, K., Aigelsreiter, A., Zinke-Cerwenka, W., Mulabecirovic, A., Kump, P. K., Halwachs, B., Gorkiewicz, G., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.154351 · Cited by 132
Fatal Aspiration Pneumonia as a Complication of Fecal Microbiota Transplant
Baxter, M., Ahmad, T., Colville, A., & Sheridan, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ247 · Cited by 126 · cited 1×
“Two deaths have been reported associated with FMT delivering procedures though mid-gut (Baxter et al., 2015; Goldenberg et al., 2018).”
BackgroundMicrobiology: Create a global microbiome effort
Dubilier, N., McFall‐Ngai, M., & Zhao, L. (2015) · Nature · doi:10.1038/526631a · Cited by 125 · cited 1×
“The sequencing of microbiota, bioinformatics technology and holistic understanding on microbiome provided new intuitionistic evidence for indicating the complex community-intrinsic properties (Dubilier et al., 2015; Madsen et al., 2017).”
Fischer, M., Kao, D., Mehta, S. R., Martin, T., Dimitry, J., Keshteli, A. H., Cook, G. K., Phelps, E., Sipe, B. W., Xu, H., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.180 · Cited by 123 · cited 2×
“A multivariable analysis (Fischer et al., 2016a, b) demonstrates that predictors of early FMT failure include severe or severe/complicated CDI, inpatient status during FMT, and previous CDI-related hospitalization.”
BackgroundMethodStärkel, P., Leclercq, S., de Timary, P., & Schnabl, B. (2018) · Clinical Science · doi:10.1042/cs20171055 · Cited by 123 · cited 1×
“In a recent study, the Yin-Yang theory (Yin and Yang) originating from traditional Chinese medicine has been proposed to explain the complex ecosystem of gut microbiota (Gibson et al., 2014; Wu et al., 2016; Starkel et al., 2018).”
BackgroundFecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease
Zhang, F.-M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.7213 · Cited by 118 · cited 2×
“…FMT was recommended for the treatment of the third occurrence of C. difficle infection in guideline FMT was not folk remedy in America since 2013 2013 (Zhang et al., 2013) Zhang et al. from China reported the FMT through mid-gut in severe fistulizing Crohn’s disease with abdominal inflammatory…”
BackgroundSelf-citationBacterial social interactions and the emergence of community-intrinsic properties
Madsen, J. S., Sørensen, S. J., & Burmølle, M. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.11.018 · Cited by 109 · cited 1×
“The sequencing of microbiota, bioinformatics technology and holistic understanding on microbiome provided new intuitionistic evidence for indicating the complex community-intrinsic properties (Dubilier et al., 2015; Madsen et al., 2017).”
Lee, C. H., Belanger, J., Kassam, Z., Smieja, M., Higgins, D., Broukhanski, G., & Kim, P. T. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2088-9 · Cited by 106 · cited 2×
“The step 2 refers to multi-FMTs and is commonly indicated to treat patients with IBD (Cui et al., 2015a, b, 2016) and partially refractory CDI (Lee et al., 2014).”
BackgroundColonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota
Peng, Z., Xiang, J., He, Z., Zhang, T., Xu, L., Cui, B., Li, P., Huang, G., Ji, G., Nie, Y., et al. (2016) · Endoscopy International Open · doi:10.1055/s-0042-105205 · Cited by 101 · cited 11×
“Among them, colonic TET does not affect the patients’ life quality.”
BackgroundSelf-citationProfiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations
Chu, N. D., Smith, M. B., Perrotta, A. R., Kassam, Z., & Alm, E. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170922 · Cited by 98 · cited 2×
“A recent study (Chu et al., 2017a, b) reported that some preparation methods can damage the content of living fecal microbes and the suitability of clinical fecal materials.”
BackgroundHe, Z., Li, P., Zhu, J., Cui, B., Xu, L., Xiang, J., Zhang, T., Long, C., Huang, G., Ji, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04984-z · Cited by 92 · cited 8×
“…(Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al., 2018), liver disease (Kao et al., 2016; Bajaj et al., 2017; Philips et al., 2017; Ren et al., 2017), blood disease (Kakihana et al., 2016; Spindelboeck et al., 2017), autism (Kang et al., 2017) and epilepsy (He et al., 2017a).”
BackgroundMethodSelf-citationEthical Issues in Fecal Microbiota Transplantation in Practice
Ma, Y., Liu, J., Rhodes, C., Nie, Y., & Zhang, F. (2017) · The American Journal of Bioethics · doi:10.1080/15265161.2017.1299240 · Cited by 91 · cited 1×
“In addition, government authorities must prioritize development of appropriate andeffective regulation of FMT to safeguard patients and donors, promote related research and avoid abuse of the treatment (Ma et al., 2017).”
BackgroundSelf-citationTreatment of Slow Transit Constipation With Fecal Microbiota Transplantation: A Pilot Study
Tian, H., Ding, C., Gong, J., Ge, X., McFarland, L. V., Gu, L., Wei, Y., Chen, Q., Zhu, W., Li, J., et al. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000472 · Cited by 81 · cited 2×
“, 2017a, b), constipation (Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al.”
BackgroundFuruya-Kanamori, L., Doi, S. A. R., Paterson, D. L., Helms, S. K., Yakob, L., McKenzie, S. J., Garborg, K., Emanuelsson, F., Stollman, N., Kronman, M. P., et al. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000511 · Cited by 76 · cited 1×
“During middle gut FMT, inappropriate techniques and procedures of infusing microbiota into the small bowel may cause adverse events, including nausea, vomiting and aspiration (Gweon et al., 2016; Furuya-Kanamori et al., 2017).”
BackgroundKelly, C. R., Kim, A. M., Laine, L., & Wu, G. D. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.028 · Cited by 74 · cited 2×
“The American Gastroenterological Association (AGA) is using data from national registry to work out a long term program that evaluates the risks and benefits of FMT for CDI (Kelly et al., 2017).”
BackgroundMethodTang, G., Yin, W., & Liu, W. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.05.007 · Cited by 72 · cited 1×
“The accumulating evidences have shown a potential role of microbiota in extra-intestinal sites, such as vagina (Klatt et al., 2017), sinus (Schwartz et al., 2016), urinary tract (Tariq et al., 2017) and skin (Chu et al., 2017a, b).”
BackgroundThe Yin and Yang of Bacterial Resilience in the Human Gut Microbiota
Gibson, M. K., Pesesky, M. W., & Dantas, G. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.05.029 · Cited by 71 · cited 1×
“In a recent study, the Yin-Yang theory (Yin and Yang) originating from traditional Chinese medicine has been proposed to explain the complex ecosystem of gut microbiota (Gibson et al., 2014; Wu et al., 2016; Starkel et al., 2018).”
BackgroundStep-up fecal microbiota transplantation (FMT) strategy
Cui, B., Li, P., Xu, L., Peng, Z., Xiang, J., He, Z., Zhang, T., Ji, G., Nie, Y., Wu, K., et al. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1151608 · Cited by 71
Self-citationKellermayer, R., Nagy-Szakal, D., Harris, A. R., Luna, R. A., Pitashny, M., Schady, D., Mir, S. A. V., Lopez, M. E., Gilger, M. A., Belmont, J., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.19 · Cited by 68 · cited 2×
“Besides, trials have revealed its potential role in dealing with refractory ulcerative colitis (Cui et al., 2015b; Kellermayer et al., 2015; Moayyedi et al., 2015; Rossen et al., 2015), Crohn’s disease (Zhang et al., 2013; Cui et al., 2015a; Shimizu et al., 2016; Bak et al., 2017; He et al., 2017a,…”
BackgroundVarier, R. U., Biltaji, E., Smith, K. J., Roberts, M. S., Kyle Jensen, M., LaFleur, J., & Nelson, R. E. (2015) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2014.80 · Cited by 68 · cited 5×
“The important events using fecal microbiota transplantation in history History of fecal microbiota transplantation (FMT) Significance of the events The fourth century (Ge 2000; Zhang et al., 2012b) Ge Hong, a Chinese doctor described the rescue for serious food poisoning, fever, diarrhea by drinking fecal water or fer…”
BackgroundInfluentialHolistic integrative medicine: toward a new era of medical advancement
Fan, D. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0499-6 · Cited by 66 · cited 2×
“Step-up FMT strategy as a holistic integrative concept (Fan 2017) focuses on the specificity of patients with steroid-dependent IBD (Cui et al.”
BackgroundSelf-citationLiu, S.-X., Li, Y.-H., Dai, W.-K., Li, X.-S., Qiu, C.-Z., Ruan, M.-L., Zou, B., Dong, C., Liu, Y.-H., He, J.-Y., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i48.8570 · Cited by 66 · cited 1×
“Liu et al. (2017) reported multiple FMTs induced remission in 17 of 19 infants with infantile allergic colitis.”
BackgroundMicrobiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease
Wu, W. H., Chen, F., Liu, Z., & Cong, Y. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000775 · Cited by 59 · cited 1×
“In a recent study, the Yin-Yang theory (Yin and Yang) originating from traditional Chinese medicine has been proposed to explain the complex ecosystem of gut microbiota (Gibson et al., 2014; Wu et al., 2016; Starkel et al., 2018).”
BackgroundYuqun, L. (2008) · Springer eBooks · doi:10.1007/978-1-4020-4425-0_8472 · Cited by 58
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis
Uygun, A., Ozturk, K., Demirci, H., Oger, C., Avci, I. Y., Turker, T., & Gulsen, M. (2017) · Medicine · doi:10.1097/md.0000000000006479 · Cited by 58
Contemporary meta-analysis of short-term Probiotic consumption on gastrointestinal transit
Miller, L. E., Zimmermann, A. K., & Ouwehand, A. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i21.5122 · Cited by 57 · cited 1×
“However, the clinical benefit of using a single species of bacteria is limited (Miller et al., 2016).”
BackgroundA novel quick transendoscopic enteral tubing in mid-gut: technique and training with video
Long, C., Yu, Y., Cui, B., Jagessar, S. A. R., Zhang, J., Ji, G., Huang, G., & Zhang, F. (2018) · BMC Gastroenterology · doi:10.1186/s12876-018-0766-2 · Cited by 57 · cited 9×
“Among them, colonic TET does not affect the patients’ life quality.”
BackgroundSelf-citationGoldenberg, S. D., Batra, R., Beales, I., Digby-Bell, J. L., Irving, P. M., Kellingray, L., Narbad, A., & Franslem-Elumogo, N. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0189-y · Cited by 56 · cited 1×
“Two deaths have been reported associated with FMT delivering procedures though mid-gut (Baxter et al., 2015; Goldenberg et al., 2018).”
BackgroundA proposed definition of microbiota transplantation for regulatory purposes
Hoffmann, D. E., Palumbo, F. B., Ravel, J., Rowthorn, V., & von Rosenvinge, E. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1293223 · Cited by 51
Improving regulation of microbiota transplants
Hoffmann, D., Palumbo, F., Ravel, J., Roghmann, M.-C., Rowthorn, V., & von Rosenvinge, E. (2017) · Science · doi:10.1126/science.aaq0034 · Cited by 51 · cited 2×
“Thus, a rapid, accurate and convenient fecal pathogen detection method is essential (Hoffmann et al., 2017a, b).”
BackgroundMethodMerlo, G., Graves, N., Brain, D., & Connelly, L. B. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13402 · Cited by 50
Baro, E., Galpérine, T., Deniès, F., Lannoy, D., Lenne, X., Odou, P., Guery, B. P., & Dervaux, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170258 · Cited by 50 · cited 3×
“…C e ll analyses of FMT for CDI in America (Konijeti et al., 2014; Varier et al., 2015), Canada (Waye et al., 2016), Australia (Merlo et al., 2016) and France (Baro et al., 2017) and IBD in China (Zhang et al., 2017) have demonstrated its significant advantage in reducing medical and social costs.”
BackgroundAndrews, P. J., & Borody, T. J. (1993) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb138063.x · Cited by 48 · cited 4×
“AD, Anno Domini; CDI, Clostridium difficile infection; FDA, Food and Drug Administration; FMT, fecal microbiota transplantation; GMP, good manufacturing practice; GvHD, graft-versus-host disease; IBS, irritable bowel disease; IBD, inflammatory bowel disease; PEG-J, percutaneous endoscopic gastro-jejunostomy; PD-1, pro…”
BackgroundInfluentialEffects of field conditions on fecal microbiota
Hale, V. L., Tan, C. L., Niu, K., Yang, Y., Cui, D., Zhao, H., Knight, R. D., & Amato, K. R. (2016) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2016.09.017 · Cited by 44 · cited 1×
“How to preserve FMT materials remains a methodological challenge (Hale et al., 2016).”
BackgroundSchwartz, J. S., Peres, A. G., Endam, L. M., Cousineau, B., Madrenas, J., & Desrosiers, M. Y. (2016) · American Journal of Rhinology and Allergy · doi:10.2500/ajra.2016.30.4372 · Cited by 42 · cited 2×
“The accumulating evidences have shown a potential role of microbiota in extra-intestinal sites, such as vagina (Klatt et al., 2017), sinus (Schwartz et al., 2016), urinary tract (Tariq et al., 2017) and skin (Chu et al., 2017a, b).”
BackgroundGweon, T.-G., Kim, J., Lim, C.-H., Park, J. M., Lee, D.-G., Lee, I. S., Cho, Y.-S., Kim, S. W., & Choi, M.-G. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2687605 · Cited by 39 · cited 1×
“During middle gut FMT, inappropriate techniques and procedures of infusing microbiota into the small bowel may cause adverse events, including nausea, vomiting and aspiration (Gweon et al., 2016; Furuya-Kanamori et al., 2017).”
BackgroundFecal microbiota transplantation for refractory Crohn's disease
Bak, S. H., Choi, H. H., Lee, J., Kim, M. H., Lee, Y. H., Kim, J. S., & Cho, Y. (2017) · Intestinal Research · doi:10.5217/ir.2017.15.2.244 · Cited by 38 · cited 1×
“…Kellermayer et al., 2015; Moayyedi et al., 2015; Rossen et al., 2015), Crohn’s disease (Zhang et al., 2013; Cui et al., 2015a; Shimizu et al., 2016; Bak et al., 2017; He et al., 2017a, b), constipation (Tian et al., 2016), irritable bowel disease (IBS) (Johnsen et al., 2018), liver disease (Kao…”
BackgroundCost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease
Zhang, T., Xiang, J., Cui, B., He, Z., Li, P., Chen, H., Xu, L., Ji, G., Nie, Y., Wu, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21491 · Cited by 34 · cited 14×
“China Press of Traditional Chinese Medicine, Beijing Xu L, Zhang T, Cui B, He Z, Xiang J, Long C, Peng Z, Li P, Huang G, Ji G et al (2016) Clinical efficacy maintains patients’ positive attitudes toward fecal microbiota transplantation.”
BackgroundSelf-citationClinical efficacy maintains patients’ positive attitudes toward fecal microbiota transplantation
Xu, L., Zhang, T., Cui, B., He, Z., Xiang, J., Long, C., Peng, Z., Li, P., Huang, G., Ji, G., et al. (2016) · Medicine · doi:10.1097/md.0000000000004055 · Cited by 31 · cited 2×
“The recent survey (Xu et al., 2016) onpatients’ attitude showed that 56.19%of 105 patients with Crohn’s disease presented satisfactory clinical efficacy and 74.29% were willing to receive the second FMT. Additionally, 89.52% (94/105) showed their willingness to recommend FMT to other patients.”
BackgroundSelf-citationA human gut ecosystem protects against C. difficile disease by targeting TcdA
Martz, S., Guzmán-Rodríguez, M., He, S.-M., Noordhof, C., Hurlbut, D. J., Gloor, G. B., Carlucci, C., Weese, J. S., Allen‐Vercoe, E., Sun, J., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1232-y · Cited by 29 · cited 1×
“The microbial ecosystem therapeutic (MET-1, or “RePOOPulate”) in pilot trials showed an attractive response (Petrof et al., 2013; Martz et al., 2017).”
BackgroundRepeated fecal microbiota transplantation in a child with ulcerative colitis
Shimizu, H., Arai, K., Abe, J., Nakabayashi, K., Yoshioka, T., Hosoi, K., & Kuroda, M. (2016) · Pediatrics International · doi:10.1111/ped.12967 · Cited by 27 · cited 2×
“Shimizu et al. (2016) reported that one child with ulcerative colitis, who was dependent on high steroid doses and did not respond to antitumor necrosis factor alpha (anti-TNF-α) treatment, achieved clinical remission and low-dose steroid dependence after multiple FMTs.”
BackgroundChinese physicians’ perceptions of fecal microbiota transplantation
Ren, R.-R., Sun, G., Yang, Y.-S., Peng, L.-H., Wang, S.-F., Shi, X.-H., Zhao, J.-Q., Ban, Y.-L., Pan, F., Wang, X.-H., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4757 · Cited by 26 · cited 1×
“The long tradition of using fecal therapy in China might contribute the high acceptance of FMT by Chinese physicians according to Yang’s survey in 2014 (Ren et al., 2016).”
BackgroundWaye, A., Atkins, K., & Kao, D. H. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000494 · Cited by 19 · cited 1×
“Most commonly, step 1 involves a single FMT for treating CDI or refractory intestinal infection (Surawicz et al., 2013; Wei et al., 2016).”
BackgroundSeth, A. K., Rawal, P., Bagga, R., & Jain, P. (2016) · Indian Journal of Gastroenterology · doi:10.1007/s12664-016-0696-2 · Cited by 18 · cited 1×
“Seth et al. (2016) reported a case of ulcerative colitis in India using multiple FMTs who maintained both clinical and endoscopic remission for more than eight months.”
BackgroundNi, X.-D., Fan, S., Zhang, Y., Wang, Z., Ding, L., Li, Y., & Li, J. (2016) · Gut and Liver · doi:10.5009/gnl15456 · Cited by 15 · cited 4×
“AD, Anno Domini; CDI, Clostridium difficile infection; FDA, Food and Drug Administration; FMT, fecal microbiota transplantation; GMP, good manufacturing practice; GvHD, graft-versus-host disease; IBS, irritable bowel disease; IBD, inflammatory bowel disease; PEG-J, percutaneous endoscopic gastro-jejunostomy; PD-1, pro…”
BackgroundInfluentialZhang, F., Amateau, S. K., Khashab, M. A., & Okolo, P. I., III (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283561f3b · Cited by 14
Self-citationMathew, J. (1993) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb138062.x · Cited by 12
Stallmach, A., Anttila, V., Hell, M., Gwynn, S., Amador, P. M., Petrosillo, N., Ráčil, Z., Warren, T., Wenisch, C., & Wilcox, M. H. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0044-100045 · Cited by 5 · cited 1×
“A multidisciplinary survey by a group of international clinicians (Stallmach et al., 2018) showed the different perceptions on the use of FMT in IBD patients.”
BackgroundFecal microbiota transplantation: understanding from holistic integrative view
Cui, B., & Zhang, F. (2018) · AME Medical Journal · doi:10.21037/amj.2017.11.13 · Cited by 2 · cited 4×
“According to this theory, the Yin-Yang balance is established between the harmful and beneficial microbial cells in the intestine, a process in which two contradictory forces complement and give rise to each other (Cui and Zhang 2018).”
BackgroundMethodSelf-citation
Research works printed but not linked: 2
- Ge H (2000) Zhou Hou Bei Ji Fang. Tianjin Science & Technology Press, Tianjin
- Xu R (2011) Chong Ding Tong Su Shang Han Lun. China Press of Traditional Chinese Medicine, Beijing
Cited by
A practical guide to amplicon and metagenomic analysis of microbiome data
Liu, Y.-X., Qin, Y., Chen, T., Lu, M., Qian, X., Guo, X., & Bai, Y. (2021) · Protein & Cell · doi:10.1007/s13238-020-00724-8 · Cited by 864
“…high-throughput sequencing (HTS) technology and data analysis methods, the roles of the microbiome in humans (Gao et al., 2018; Yang and Yu, 2018; Zhang et al., 2018a), animals (Liu et al., 2020), plants (Liu et al., 2019a; Wang et al., 2020a), and the environment (Mahnert et al., 2019; Zheng et…”
BackgroundMethodHigh-throughput cultivation and identification of bacteria from the plant root microbiota
Zhang, J., Liu, Y.-X., Guo, X., Qin, Y., Garrido-Oter, R., Schulze-Lefert, P., & Bai, Y. (2021) · Nature Protocols · doi:10.1038/s41596-020-00444-7 · Cited by 285
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Gut-Brain Psychology: Rethinking Psychology From the Microbiota–Gut–Brain Axis
Liang, S., Wu, X., & Jin, F. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00033 · Cited by 263
“…by microbiota intervention using probiotics, prebiotics, and FMT have increased steadily (Cryan and Dinan, 2012; Dinan et al., 2013; Liang et al., 2015; Pirbaglou et al., 2016; He et al., 2017; Kang et al., 2017; Mika et al., 2017; Zhao et al., 2017; Bruce-Keller et al., 2018; Yang et al., 2018).”
BackgroundZhang, T., Lu, G., Zhao, Z., Liu, Y., Shen, Q., Li, P., Chen, Y., Yin, H., Wang, H., Marcella, C., et al. (2020) · Protein & Cell · doi:10.1007/s13238-019-00684-8 · Cited by 260
“Themethod for preparation ofmicrobiota is basedon theautomatic microbiota purification system followed with centrifugation plus suspension for three times in a specially designed exclusive laboratory at goodmanufacture practice (GMP) level (Cui et al., 2016; Zhang et al., 2018).”
MethodInfluentialSelf-citation
Metadata
- Authors
- FMT-standardization Study Group, Zhang, F., Cui, B., He, X., Nie, Y., Wu, K., & Fan, D.
- Affiliations
- Sir Run Run Shaw Hospital (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Corresponding author
- Zhang, Faming
- Venue
- Protein & Cell
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-24
- Volume
- 9
- Issue
- 5
- Pages
- 462-473
- ISSN
- 1674-800X (ISSN-L)
- 1674-8018
- PMC
- PMC5960466
- OpenAlex
- W2800200239
- Semantic Scholar
- ff8600aed48167ea90e4a478426d6851b5788a7b
- Cited by
- 300
- References
- 105
- Citations by year
- 2026: 18 · 2025: 40 · 2024: 41 · 2023: 44 · 2022: 45 · 2021: 40 · 2020: 38 · 2019: 21 · 2018: 12
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Protein & Cell (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81600417, 81670495, 2015BAI13B07)
- Government of Jiangsu Province
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, microbiota-host interactions, Clostridium difficile infection, inflammatory bowel disease, diabetes mellitus, gut-brain axis
- MeSH terms
- Fecal Microbiota Transplantation, Host Microbial Interactions, Clostridium Infections, Humans, Metabolic Diseases, Inflammatory Bowel Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.